Albert Labs has highlighted that the UK’s new guidance on Real-World data will accelerate access to psychedelic treatments.
A review has shown that ketamine therapy is able to rapidly reduce symptoms of depression and suicidal thoughts in the short-term.
The groundbreaking study will now be expanded to explore the use of ketamine for treating binge eating disorder, compulsive sexual behaviour and internet gaming disorder.
A new collaboration is aiming to develop psychedelic medicines to address the unique needs of people living with a variety of mental health conditions.
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
UK company Clerkenwell Health is working to develop a gold standard in the delivery of psychedelic care.
One company is providing investors with the opportunity to contribute to novel mental health care solutions by participating in the growth of companies in the psychedelics...
Mydecine Innovations Group recently signed a five-year agreement with Johns Hopkins University School of Medicine that will advance research on novel psychedelic therapy.
Return Health is exploring psychedelic derivatives for the treatment of dementia.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
